Guardian Pharmacy Reports Strong 2025 Results, Swings to Profitability with 17.9% Revenue Growth
GRDN sits 85% above its 52-week low of $18.37 on elevated volume (2.4× avg).
Summary
Guardian Pharmacy Services, Inc. announced a significant financial improvement for fiscal year 2025, achieving net income of $49.2 million compared to a $110 million net loss in 2024, driven by 17.9% revenue growth and strong Adjusted EBITDA.
Key Events · Earnings and Guidance · GRDN
-
Significant Swing to Profitability
The company reported net income attributable to Guardian Pharmacy Services, Inc. of $49.2 million for the year ended December 31, 2025, a substantial improvement from a net loss of $110.0 million in 2024.
-
Strong Revenue Growth
Revenues increased by 17.9% to $1.45 billion in 2025, up from $1.23 billion in 2024, driven by organic growth and acquisitions.
-
Increased Adjusted EBITDA
Adjusted EBITDA grew by 26.8% to $115.1 million in 2025, compared to $90.8 million in 2024, indicating improved operational performance.
-
Enhanced Liquidity and Debt Management
Cash and cash equivalents significantly increased to $65.6 million as of December 31, 2025, from $4.7 million in 2024. The company also has no outstanding amounts under its Term Loan or Line of Credit, which was extended to April 23, 2027.
Analysis · GRDN · Trade & Services
Guardian Pharmacy Services, Inc. reported a significant financial turnaround for the fiscal year ended December 31, 2025, moving from a substantial net loss in 2024 to strong profitability. This annual report confirms and expands upon the robust Q4 results previously announced, providing comprehensive financial details. The company's impressive revenue growth, coupled with a healthy increase in Adjusted EBITDA and a strong cash position with no outstanding debt on its credit facility, signals improved operational efficiency and financial stability. While founders sold a notable amount of shares in a May 2025 follow-on offering, the company's portion of the proceeds was used for share repurchases, mitigating direct dilution from the company's perspective. The overall picture is one of strong performance and positive momentum.
At the time of this filing, GRDN was trading at $34.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $18.37 to $37.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.